Subject: Blinatumomab Effective for Children with Relapsed Leukemia - Cancer Currents Blog
From: National Cancer Institute <[email-masked]>
To: [email-masked]
Date: Thu, 01 Apr 2021 18:02:29 +0000

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

Blinatumomab Improves Survival in Children with Relapsed Leukemia

04/01/2021

The results of two trials establish blinatumomab (Blincyto) as a new standard treatment for children and young adults with high-risk relapsed B-cell acute lymphoblastic leukemia after remission has been achieved and before a stem cell transplant.

Stay Connected with the National Cancer Institute

Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237)

SUBSCRIBER SERVICES:
Manage Subscriptions  |  Help

This email was sent to [email-masked] using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892